Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta
- 30 June 2009
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 31 (6) , 1142-1157
- https://doi.org/10.1016/j.clinthera.2009.06.007
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]Neurology, 2002
- European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosisAnnals of Neurology, 2001
- Relapses and Progression of Disability in Multiple SclerosisNew England Journal of Medicine, 2000
- Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisThe Lancet, 1998
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDYBrain, 1989